Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS),also known as National Institutes of Health(NIH)type Ⅲ prostatitis,is a common disorder with an unclear etiology and no known curative treatments.Based on the...Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS),also known as National Institutes of Health(NIH)type Ⅲ prostatitis,is a common disorder with an unclear etiology and no known curative treatments.Based on the presence or absence of leukocytes in expressed prostatic secretion(EPS),CP/CPPS is classifiedfurther into Illa(inflammatory)and Illb(noninflammatory)subtypes.However,the severity of symptoms is not entirely consistent with the white blood cell(WBC)count.Following the preliminary finding of a link between inflammatory cytokines and CP/CPPS,we performed this clinical study with the aim of identifying cytokines that are differentially expressed according to whether the prostatitis subtype is Ⅲa or Ⅲb.We found that granulocyte colony-stimulating factor(G-CSF),interleukin-18(IL-18),and monocyte chemoattractant protein-1(MCP-1)levels were significantly elevated and interferon-inducible protein-10(IP-10)and platelet-derived growth factor-BB(PDGF-BB)levels were downregulated in the EPS of patients with type Ⅲa prostatitis.In a word,it is a meaningful study in which we investigate the levels of various cytokines in EPS according to whether prostatitis is the Ⅲa or Ⅲb subtype.The combination of G-CSF,IL-18,MCP-1,IP-10,and PDGF-BB expression levels could form a basis for classification,diagnosis,and therapeutic targets in clinical P/CPPS.展开更多
AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 female...AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis.展开更多
目的:研究针刺曲骨穴辅助治疗Ⅲ型前列腺炎(CP/CPPS)的近远期疗效。方法:将90例CP/CPPS患者按数字表法随机分为两组,对照组45例用甲磺酸左氧氟沙星片0.5 g口服,1次/d+盐酸特拉唑嗪片2 mg睡前服,治疗组45例在对照组治疗基础上加针刺曲骨...目的:研究针刺曲骨穴辅助治疗Ⅲ型前列腺炎(CP/CPPS)的近远期疗效。方法:将90例CP/CPPS患者按数字表法随机分为两组,对照组45例用甲磺酸左氧氟沙星片0.5 g口服,1次/d+盐酸特拉唑嗪片2 mg睡前服,治疗组45例在对照组治疗基础上加针刺曲骨穴进行治疗,疗程均为4周。疗程结束后,所有病例4周后均随访,记录复发人数及复发时间,计算并比较治疗后两组间NIH慢性前列腺炎症状评分表(CPSI)、生活质量(QoL)评分、Zung抑郁量表评分以及复发率和复发时间。结果:治疗后,治疗组尿频、尿急、尿不尽、小腹会阴疼痛不适、抑郁情绪等症状明显缓解;与对照组比较,治疗组CPSI(8.6±2.12 vs 6.2±2.25,P<0.05)、QoL评分(6.0±1.33 vs 3.4±1.71,P<0.01)、Zung评分(43.9±4.53 vs 33.6±3.20,P<0.01)显著下降,差异明显。结论:针刺曲骨穴辅助治疗CP/CPPS,可明显改善患者的临床症状、提高抗菌药物的治疗效果,并有助于减少CP/CPPS的复发率、延长复发时间。展开更多
文摘Chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS),also known as National Institutes of Health(NIH)type Ⅲ prostatitis,is a common disorder with an unclear etiology and no known curative treatments.Based on the presence or absence of leukocytes in expressed prostatic secretion(EPS),CP/CPPS is classifiedfurther into Illa(inflammatory)and Illb(noninflammatory)subtypes.However,the severity of symptoms is not entirely consistent with the white blood cell(WBC)count.Following the preliminary finding of a link between inflammatory cytokines and CP/CPPS,we performed this clinical study with the aim of identifying cytokines that are differentially expressed according to whether the prostatitis subtype is Ⅲa or Ⅲb.We found that granulocyte colony-stimulating factor(G-CSF),interleukin-18(IL-18),and monocyte chemoattractant protein-1(MCP-1)levels were significantly elevated and interferon-inducible protein-10(IP-10)and platelet-derived growth factor-BB(PDGF-BB)levels were downregulated in the EPS of patients with type Ⅲa prostatitis.In a word,it is a meaningful study in which we investigate the levels of various cytokines in EPS according to whether prostatitis is the Ⅲa or Ⅲb subtype.The combination of G-CSF,IL-18,MCP-1,IP-10,and PDGF-BB expression levels could form a basis for classification,diagnosis,and therapeutic targets in clinical P/CPPS.
文摘AIM:To test whether colchicine would be an effective antif ibrotic agent for treatment of chronic liver diseases in patients who could not be treated with α-interferon.METHODS:Seventy-four patients(46 males,28 females) aged 40-66 years(mean 53±13 years) participated in the study.The patients were affected by chronic liver diseases with cirrhosis which was proven histologically(n=58);by chronic active hepatitis C(n=4),chronic active hepatitis B(n=2),and chronic persistent hepatitis C(n=6).In the four patients lacking histology,cirrhosis was diagnosed from anamnesis,serum laboratory tests,esophageal varices and ascites.Patients were assigned to colchicine(1 mg/d) or standard treatment as control in a randomized,double-blind trial,and followed for 4.4 years with clinical and laboratory evaluation.RESULTS:Survival at the end of the study was 94.6% in the colchicine group and 78.4% in the control group(P=0.001).Serum N-terminal peptide of type Ⅲ procollagen levels fell from 34.0 to 18.3 ng/mL(P=0.0001),and pseudocholinesterase levels rose from 4.900 to 5.610 mU/mL(P=0.0001) in the colchicine group,while no signif icant change was seen in controls.Best results were obtained in patients with chronic hepatitis C and in alcoholic cirrhotics.CONCLUSION:Colchicine is an effective and safe antifibrotic drug for long-term treatment of chronic liver disease in which fi brosis progresses towards cirrhosis.
文摘目的:研究针刺曲骨穴辅助治疗Ⅲ型前列腺炎(CP/CPPS)的近远期疗效。方法:将90例CP/CPPS患者按数字表法随机分为两组,对照组45例用甲磺酸左氧氟沙星片0.5 g口服,1次/d+盐酸特拉唑嗪片2 mg睡前服,治疗组45例在对照组治疗基础上加针刺曲骨穴进行治疗,疗程均为4周。疗程结束后,所有病例4周后均随访,记录复发人数及复发时间,计算并比较治疗后两组间NIH慢性前列腺炎症状评分表(CPSI)、生活质量(QoL)评分、Zung抑郁量表评分以及复发率和复发时间。结果:治疗后,治疗组尿频、尿急、尿不尽、小腹会阴疼痛不适、抑郁情绪等症状明显缓解;与对照组比较,治疗组CPSI(8.6±2.12 vs 6.2±2.25,P<0.05)、QoL评分(6.0±1.33 vs 3.4±1.71,P<0.01)、Zung评分(43.9±4.53 vs 33.6±3.20,P<0.01)显著下降,差异明显。结论:针刺曲骨穴辅助治疗CP/CPPS,可明显改善患者的临床症状、提高抗菌药物的治疗效果,并有助于减少CP/CPPS的复发率、延长复发时间。
